BUSINESS
    Amvuttra Key to Alnylam Japan’s 25%-Plus CAGR Goal through 2030
    By Hayate Horiguchi August 20, 2026
    RNAi specialist Alnylam Japan is targeting a compound annual growth rate (CAGR) of at least 25% from 2026 through 2030, with Amvuttra (vutrisiran) expected to serve as a key growth driver following its label expansion…

    LATEST

    Biogen Japan President Den Tapped as Chief of Staff to Global CEO
    August 20, 2026
    Biogen Japan President Takatsugu Den is moving to the US biotech’s Cambridge, Massachusetts, headquarters to become chief of staff to CEO Chris Viehbacher, effective October 1, the company said on August 20.Den, who has spearheaded…
    Japan Panel to Discuss Approval of 6 NMEs, Leqembi SC on Aug. 26
    August 20, 2026
    A Japanese health ministry panel will meet on August 26 to review whether to recommend approval for six new molecular entities (NMEs) and a subcutaneous formulation of Eisai’s Alzheimer’s therapy Leqembi (lecanemab), alongside other label…
    9 Drugs Top 100 Billion Yen in FY2025 Japan Sales; Keytruda Retains Crown: Jiho Tally
    August 20, 2026
    Nine prescription drugs generated domestic sales of more than 100 billion yen in FY2025, three more than a year earlier, according to a Jiho tally, with MSD’s Keytruda (pembrolizumab) retaining the top spot for the…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COMMENTARY

    Signs of Shift in Japan’s Drug Policy, but Cost Pressures Persist
    By Kohei Hori

    Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…

    COLUMN

    Why Your Brain Wants You to Stay (Even When You Want to Go)
    By Philip Carrigan

    A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA